Matthew McQueen
Concepts (506)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 22 | 2022 | 1414 | 1.850 |
Why?
| | Polymorphism, Single Nucleotide | 40 | 2020 | 2152 | 1.690 |
Why?
| | Genetic Predisposition to Disease | 26 | 2022 | 2371 | 1.330 |
Why?
| | Genetic Linkage | 10 | 2011 | 273 | 1.260 |
Why?
| | Troponin I | 9 | 2020 | 72 | 1.090 |
Why?
| | Troponin T | 9 | 2020 | 65 | 1.020 |
Why?
| | Waist-Height Ratio | 3 | 2016 | 8 | 0.980 |
Why?
| | Risk-Taking | 4 | 2015 | 328 | 0.810 |
Why?
| | Body Mass Index | 12 | 2015 | 2439 | 0.770 |
Why?
| | Genetic Testing | 9 | 2016 | 482 | 0.690 |
Why?
| | Acute Coronary Syndrome | 6 | 2020 | 295 | 0.670 |
Why?
| | Sexual Behavior | 3 | 2013 | 492 | 0.650 |
Why?
| | Bipolar Disorder | 5 | 2011 | 281 | 0.610 |
Why?
| | Siblings | 7 | 2014 | 195 | 0.610 |
Why?
| | Alcohol Drinking | 7 | 2022 | 826 | 0.610 |
Why?
| | Quantitative Trait, Heritable | 5 | 2016 | 118 | 0.560 |
Why?
| | Genome, Human | 9 | 2014 | 422 | 0.550 |
Why?
| | Genotype | 18 | 2019 | 1845 | 0.550 |
Why?
| | Epidemiology | 1 | 2018 | 33 | 0.550 |
Why?
| | Myocardial Infarction | 10 | 2020 | 1211 | 0.530 |
Why?
| | Cardiovascular Diseases | 13 | 2024 | 2182 | 0.530 |
Why?
| | Metabolic Syndrome | 2 | 2016 | 356 | 0.520 |
Why?
| | Quantitative Trait Loci | 4 | 2015 | 374 | 0.520 |
Why?
| | Substance-Related Disorders | 8 | 2020 | 1094 | 0.500 |
Why?
| | Databases, Genetic | 5 | 2012 | 249 | 0.480 |
Why?
| | Antisocial Personality Disorder | 2 | 2015 | 121 | 0.470 |
Why?
| | Brain Concussion | 2 | 2021 | 640 | 0.470 |
Why?
| | Alzheimer Disease | 8 | 2011 | 622 | 0.460 |
Why?
| | Teaching | 1 | 2018 | 240 | 0.460 |
Why?
| | Longitudinal Studies | 15 | 2024 | 2959 | 0.450 |
Why?
| | Waist Circumference | 1 | 2015 | 141 | 0.450 |
Why?
| | Education, Medical, Undergraduate | 1 | 2018 | 207 | 0.450 |
Why?
| | Receptors, Nicotinic | 7 | 2013 | 323 | 0.450 |
Why?
| | Alcoholism | 8 | 2020 | 817 | 0.450 |
Why?
| | Athletic Injuries | 2 | 2021 | 571 | 0.430 |
Why?
| | Humans | 122 | 2024 | 145305 | 0.430 |
Why?
| | Genetic Variation | 8 | 2022 | 986 | 0.430 |
Why?
| | Tobacco Use Disorder | 6 | 2020 | 218 | 0.420 |
Why?
| | Obesity | 9 | 2016 | 3085 | 0.410 |
Why?
| | Impulsive Behavior | 1 | 2015 | 146 | 0.390 |
Why?
| | Gene-Environment Interaction | 2 | 2014 | 182 | 0.390 |
Why?
| | Blood Pressure | 8 | 2018 | 1771 | 0.380 |
Why?
| | Public Health | 1 | 2018 | 566 | 0.380 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 2118 | 0.380 |
Why?
| | Conduct Disorder | 5 | 2015 | 160 | 0.360 |
Why?
| | Aging | 6 | 2020 | 1968 | 0.360 |
Why?
| | Male | 74 | 2024 | 72628 | 0.360 |
Why?
| | Breast Feeding | 1 | 2015 | 448 | 0.350 |
Why?
| | Natriuretic Peptide, Brain | 4 | 2024 | 111 | 0.340 |
Why?
| | Female | 71 | 2024 | 78605 | 0.340 |
Why?
| | Genetic Loci | 4 | 2022 | 261 | 0.330 |
Why?
| | Phenotype | 17 | 2020 | 3172 | 0.330 |
Why?
| | Sodium, Dietary | 4 | 2018 | 37 | 0.330 |
Why?
| | Sodium | 3 | 2018 | 197 | 0.320 |
Why?
| | Carrier State | 2 | 2021 | 79 | 0.320 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2010 | 46 | 0.300 |
Why?
| | Myocardium | 3 | 2020 | 940 | 0.300 |
Why?
| | Clinical Laboratory Techniques | 3 | 2020 | 96 | 0.290 |
Why?
| | Pedigree | 3 | 2013 | 514 | 0.290 |
Why?
| | Apolipoprotein E4 | 2 | 2007 | 41 | 0.280 |
Why?
| | Adult | 36 | 2020 | 40627 | 0.280 |
Why?
| | Risk Factors | 26 | 2022 | 10816 | 0.270 |
Why?
| | Apolipoprotein E2 | 1 | 2007 | 3 | 0.270 |
Why?
| | alpha-Macroglobulins | 1 | 2007 | 25 | 0.270 |
Why?
| | Biometry | 2 | 2007 | 68 | 0.260 |
Why?
| | Body Weight | 5 | 2015 | 980 | 0.260 |
Why?
| | Adolescent | 25 | 2021 | 22507 | 0.250 |
Why?
| | Young Adult | 17 | 2021 | 14163 | 0.250 |
Why?
| | Multifactorial Inheritance | 2 | 2022 | 203 | 0.240 |
Why?
| | Emergency Service, Hospital | 8 | 2020 | 2328 | 0.240 |
Why?
| | Middle Aged | 35 | 2024 | 36021 | 0.240 |
Why?
| | Blood Glucose | 9 | 2018 | 2333 | 0.240 |
Why?
| | Family | 7 | 2011 | 682 | 0.230 |
Why?
| | Linkage Disequilibrium | 7 | 2020 | 249 | 0.230 |
Why?
| | Sodium Nitrite | 2 | 2015 | 39 | 0.230 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2005 | 38 | 0.230 |
Why?
| | Models, Genetic | 8 | 2016 | 536 | 0.220 |
Why?
| | Aged | 32 | 2024 | 26001 | 0.220 |
Why?
| | Memory | 1 | 2007 | 296 | 0.220 |
Why?
| | Biomarkers | 11 | 2024 | 4284 | 0.220 |
Why?
| | Asymptomatic Infections | 2 | 2021 | 37 | 0.210 |
Why?
| | Filgrastim | 1 | 2024 | 13 | 0.210 |
Why?
| | Diet, Sodium-Restricted | 2 | 2016 | 38 | 0.210 |
Why?
| | Internationality | 2 | 2022 | 156 | 0.210 |
Why?
| | Endothelium, Vascular | 3 | 2016 | 965 | 0.210 |
Why?
| | Heart Diseases | 2 | 2017 | 350 | 0.200 |
Why?
| | Feeding and Eating Disorders | 2 | 2020 | 165 | 0.200 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2024 | 28 | 0.200 |
Why?
| | HIV Infections | 3 | 2013 | 3158 | 0.200 |
Why?
| | Population Health | 1 | 2024 | 44 | 0.200 |
Why?
| | Health Status | 2 | 2018 | 837 | 0.190 |
Why?
| | Cooperative Behavior | 1 | 2005 | 467 | 0.190 |
Why?
| | Cholesterol, HDL | 3 | 2016 | 200 | 0.190 |
Why?
| | ROC Curve | 4 | 2017 | 615 | 0.190 |
Why?
| | Saliva | 2 | 2021 | 249 | 0.180 |
Why?
| | Prospective Studies | 10 | 2021 | 8011 | 0.180 |
Why?
| | Viral Load | 2 | 2021 | 527 | 0.180 |
Why?
| | Nerve Tissue Proteins | 4 | 2011 | 593 | 0.180 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3419 | 0.180 |
Why?
| | Tobacco Use | 1 | 2022 | 61 | 0.180 |
Why?
| | Case-Control Studies | 15 | 2019 | 3613 | 0.180 |
Why?
| | Peptide Fragments | 4 | 2024 | 699 | 0.170 |
Why?
| | Lipids | 3 | 2018 | 712 | 0.170 |
Why?
| | Hypertension | 4 | 2016 | 1266 | 0.170 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2012 | 62 | 0.170 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 764 | 0.170 |
Why?
| | Prediabetic State | 1 | 2024 | 246 | 0.170 |
Why?
| | Smoking | 5 | 2019 | 1472 | 0.160 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 1138 | 0.160 |
Why?
| | Receptors, GABA-A | 2 | 2014 | 138 | 0.160 |
Why?
| | Gastrointestinal Microbiome | 2 | 2020 | 772 | 0.160 |
Why?
| | Diseases in Twins | 2 | 2012 | 115 | 0.160 |
Why?
| | Alleles | 5 | 2018 | 881 | 0.160 |
Why?
| | Mental Disorders | 3 | 2019 | 1173 | 0.160 |
Why?
| | Gene Frequency | 10 | 2011 | 481 | 0.160 |
Why?
| | Brachial Artery | 3 | 2016 | 206 | 0.160 |
Why?
| | Risk | 4 | 2020 | 912 | 0.150 |
Why?
| | Immunoassay | 1 | 2020 | 109 | 0.150 |
Why?
| | Reference Values | 4 | 2016 | 798 | 0.150 |
Why?
| | Genetic Markers | 4 | 2014 | 332 | 0.150 |
Why?
| | Multigene Family | 2 | 2011 | 207 | 0.150 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 655 | 0.150 |
Why?
| | Risk Assessment | 8 | 2020 | 3686 | 0.150 |
Why?
| | Data Interpretation, Statistical | 3 | 2011 | 372 | 0.140 |
Why?
| | Minisatellite Repeats | 1 | 2019 | 36 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 108 | 0.140 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 271 | 0.140 |
Why?
| | Global Health | 4 | 2016 | 403 | 0.140 |
Why?
| | Behavior | 1 | 2019 | 91 | 0.140 |
Why?
| | Schizophrenia | 3 | 2020 | 446 | 0.140 |
Why?
| | Adolescent Behavior | 2 | 2013 | 501 | 0.140 |
Why?
| | Healthy Aging | 1 | 2018 | 40 | 0.140 |
Why?
| | Vascular Stiffness | 3 | 2018 | 487 | 0.140 |
Why?
| | Genetic Association Studies | 4 | 2014 | 373 | 0.130 |
Why?
| | Biological Specimen Banks | 1 | 2019 | 105 | 0.130 |
Why?
| | Feces | 2 | 2020 | 514 | 0.130 |
Why?
| | Pandemics | 2 | 2024 | 1698 | 0.130 |
Why?
| | Sodium Pertechnetate Tc 99m | 2 | 1997 | 4 | 0.130 |
Why?
| | Marijuana Abuse | 1 | 2020 | 211 | 0.130 |
Why?
| | NAD | 1 | 2018 | 82 | 0.130 |
Why?
| | Likelihood Functions | 2 | 2015 | 143 | 0.130 |
Why?
| | Niacinamide | 1 | 2018 | 86 | 0.130 |
Why?
| | Body Height | 2 | 2015 | 202 | 0.130 |
Why?
| | Students | 2 | 2021 | 663 | 0.130 |
Why?
| | Caloric Restriction | 2 | 2018 | 127 | 0.130 |
Why?
| | Athletes | 1 | 2021 | 420 | 0.130 |
Why?
| | Mouth | 1 | 2017 | 88 | 0.130 |
Why?
| | Cholesterol, LDL | 2 | 2016 | 359 | 0.130 |
Why?
| | Exercise | 3 | 2018 | 2206 | 0.130 |
Why?
| | Apolipoprotein B-100 | 1 | 2016 | 13 | 0.130 |
Why?
| | Hair | 2 | 2015 | 88 | 0.120 |
Why?
| | Psychological Trauma | 1 | 2017 | 57 | 0.120 |
Why?
| | Apolipoprotein A-I | 1 | 2016 | 39 | 0.120 |
Why?
| | Burns | 1 | 2021 | 377 | 0.120 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2016 | 41 | 0.120 |
Why?
| | Regional Blood Flow | 2 | 2016 | 514 | 0.120 |
Why?
| | Chromosome Mapping | 5 | 2015 | 510 | 0.120 |
Why?
| | Trehalose | 1 | 2016 | 35 | 0.120 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2016 | 37 | 0.120 |
Why?
| | Europe | 5 | 2022 | 416 | 0.120 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 465 | 0.120 |
Why?
| | Gene Regulatory Networks | 2 | 2018 | 321 | 0.110 |
Why?
| | Cross-Sectional Studies | 6 | 2013 | 5883 | 0.110 |
Why?
| | Algorithms | 3 | 2020 | 1846 | 0.110 |
Why?
| | Cohort Studies | 9 | 2020 | 5982 | 0.110 |
Why?
| | Sexual Partners | 2 | 2013 | 192 | 0.110 |
Why?
| | Educational Status | 2 | 2014 | 467 | 0.110 |
Why?
| | Aged, 80 and over | 7 | 2020 | 8295 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 26 | 0.110 |
Why?
| | Amino Acids | 1 | 2018 | 522 | 0.110 |
Why?
| | Carotid Arteries | 1 | 2015 | 207 | 0.100 |
Why?
| | Quality Control | 1 | 2014 | 163 | 0.100 |
Why?
| | United States | 5 | 2016 | 16051 | 0.100 |
Why?
| | Health Surveys | 1 | 2016 | 518 | 0.100 |
Why?
| | Odds Ratio | 6 | 2016 | 1077 | 0.100 |
Why?
| | Proteome | 1 | 2018 | 518 | 0.100 |
Why?
| | Malawi | 1 | 2013 | 57 | 0.100 |
Why?
| | Hindlimb | 1 | 2014 | 131 | 0.100 |
Why?
| | Income | 1 | 2014 | 202 | 0.100 |
Why?
| | Albuminuria | 1 | 2014 | 190 | 0.100 |
Why?
| | Polymorphism, Genetic | 3 | 2012 | 612 | 0.100 |
Why?
| | Locomotion | 1 | 2014 | 105 | 0.100 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 22 | 0.100 |
Why?
| | Metformin | 1 | 2016 | 320 | 0.100 |
Why?
| | Colorado | 4 | 2021 | 4579 | 0.100 |
Why?
| | Physical Exertion | 1 | 2014 | 207 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 134 | 0.090 |
Why?
| | Transplantation | 1 | 2013 | 33 | 0.090 |
Why?
| | Metabolic Networks and Pathways | 1 | 2014 | 187 | 0.090 |
Why?
| | Telomere | 1 | 2016 | 289 | 0.090 |
Why?
| | Aorta | 1 | 2015 | 431 | 0.090 |
Why?
| | Double-Blind Method | 5 | 2018 | 2033 | 0.090 |
Why?
| | Metabolomics | 1 | 2018 | 727 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2024 | 2592 | 0.090 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 90 | 0.090 |
Why?
| | Receptors, Oxytocin | 1 | 2012 | 20 | 0.090 |
Why?
| | Myocardial Ischemia | 1 | 2014 | 286 | 0.090 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1391 | 0.090 |
Why?
| | Lovastatin | 1 | 1992 | 37 | 0.090 |
Why?
| | Pravastatin | 1 | 1992 | 44 | 0.090 |
Why?
| | Canada | 5 | 2007 | 429 | 0.090 |
Why?
| | Substance Abuse, Intravenous | 1 | 2013 | 128 | 0.090 |
Why?
| | Hyperlipoproteinemia Type II | 1 | 1992 | 32 | 0.090 |
Why?
| | Genetic Heterogeneity | 3 | 2008 | 65 | 0.090 |
Why?
| | Puberty | 1 | 2013 | 140 | 0.090 |
Why?
| | Haplotypes | 6 | 2010 | 490 | 0.090 |
Why?
| | Age Factors | 6 | 2020 | 3339 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 612 | 0.090 |
Why?
| | Prevalence | 6 | 2017 | 2838 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2021 | 1992 | 0.090 |
Why?
| | Ramipril | 2 | 2008 | 6 | 0.090 |
Why?
| | Physical Fitness | 1 | 2013 | 209 | 0.090 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2011 | 8 | 0.090 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2011 | 36 | 0.080 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2011 | 55 | 0.080 |
Why?
| | Interleukins | 1 | 2013 | 248 | 0.080 |
Why?
| | Potassium | 1 | 2011 | 152 | 0.080 |
Why?
| | Receptors, Immunologic | 2 | 2013 | 208 | 0.080 |
Why?
| | Receptors, Dopamine D4 | 1 | 2011 | 26 | 0.080 |
Why?
| | Postural Balance | 1 | 2014 | 240 | 0.080 |
Why?
| | Software | 2 | 2014 | 692 | 0.080 |
Why?
| | Motor Activity | 1 | 2015 | 725 | 0.080 |
Why?
| | Glucose Metabolism Disorders | 1 | 2010 | 11 | 0.080 |
Why?
| | Behavior, Animal | 1 | 2014 | 522 | 0.080 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2011 | 59 | 0.080 |
Why?
| | Child Behavior Disorders | 1 | 2011 | 118 | 0.080 |
Why?
| | Diabetes Mellitus | 3 | 2011 | 1098 | 0.080 |
Why?
| | Follow-Up Studies | 6 | 2024 | 5431 | 0.080 |
Why?
| | Catechol O-Methyltransferase | 1 | 2010 | 20 | 0.080 |
Why?
| | Hepatitis C | 1 | 2013 | 254 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 226 | 0.080 |
Why?
| | Diet, Reducing | 1 | 2010 | 91 | 0.080 |
Why?
| | Life Expectancy | 1 | 2010 | 72 | 0.080 |
Why?
| | Twins, Dizygotic | 1 | 2010 | 109 | 0.080 |
Why?
| | Tissue Donors | 1 | 2013 | 426 | 0.070 |
Why?
| | Environment | 2 | 2010 | 306 | 0.070 |
Why?
| | Microbiota | 1 | 2017 | 781 | 0.070 |
Why?
| | Psychology, Adolescent | 1 | 2009 | 63 | 0.070 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 134 | 0.070 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2017 | 893 | 0.070 |
Why?
| | Isotretinoin | 1 | 2009 | 26 | 0.070 |
Why?
| | Quality of Life | 1 | 2021 | 3197 | 0.070 |
Why?
| | Hyperhomocysteinemia | 1 | 2009 | 27 | 0.070 |
Why?
| | Ontario | 2 | 2020 | 96 | 0.070 |
Why?
| | Insulin Glargine | 2 | 2022 | 88 | 0.070 |
Why?
| | Acne Vulgaris | 1 | 2009 | 25 | 0.070 |
Why?
| | Hypertriglyceridemia | 1 | 2009 | 44 | 0.070 |
Why?
| | Energy Metabolism | 1 | 2015 | 946 | 0.070 |
Why?
| | Genes, Neoplasm | 1 | 2008 | 25 | 0.070 |
Why?
| | Longevity | 1 | 2010 | 174 | 0.070 |
Why?
| | Benzoates | 1 | 2008 | 50 | 0.070 |
Why?
| | Dermatologic Agents | 1 | 2009 | 68 | 0.070 |
Why?
| | Homocysteine | 1 | 2009 | 152 | 0.070 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 38 | 0.070 |
Why?
| | Raphe Nuclei | 2 | 1999 | 111 | 0.070 |
Why?
| | Myosin Type V | 1 | 2008 | 9 | 0.070 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6079 | 0.070 |
Why?
| | Proteinuria | 1 | 2008 | 103 | 0.070 |
Why?
| | Universities | 2 | 2021 | 453 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 178 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2926 | 0.060 |
Why?
| | Benzimidazoles | 1 | 2008 | 190 | 0.060 |
Why?
| | Cognition | 1 | 2015 | 1271 | 0.060 |
Why?
| | Death | 2 | 2018 | 131 | 0.060 |
Why?
| | Myosin Heavy Chains | 1 | 2008 | 185 | 0.060 |
Why?
| | Triglycerides | 2 | 2003 | 521 | 0.060 |
Why?
| | Prognosis | 4 | 2021 | 4310 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 1 | 2006 | 57 | 0.060 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 198 | 0.060 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 428 | 0.060 |
Why?
| | Antigens, Neoplasm | 1 | 2008 | 272 | 0.060 |
Why?
| | Pharmacogenetics | 1 | 2007 | 173 | 0.060 |
Why?
| | China | 3 | 2007 | 270 | 0.060 |
Why?
| | Sex Factors | 4 | 2017 | 2115 | 0.060 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2005 | 25 | 0.060 |
Why?
| | Heart Failure | 2 | 2011 | 2331 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2013 | 827 | 0.060 |
Why?
| | Parkinson Disease | 1 | 2012 | 600 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2005 | 119 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2008 | 501 | 0.060 |
Why?
| | Biological Availability | 2 | 2012 | 142 | 0.050 |
Why?
| | Hematologic Agents | 1 | 2024 | 3 | 0.050 |
Why?
| | Febrile Neutropenia | 1 | 2024 | 6 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2008 | 630 | 0.050 |
Why?
| | Chemical Phenomena | 1 | 2024 | 81 | 0.050 |
Why?
| | Ankle Brachial Index | 1 | 2024 | 41 | 0.050 |
Why?
| | Comorbidity | 4 | 2013 | 1661 | 0.050 |
Why?
| | Anxiety Disorders | 2 | 2021 | 373 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1260 | 0.050 |
Why?
| | Metabolome | 2 | 2018 | 385 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 205 | 0.050 |
Why?
| | Cognition Disorders | 1 | 2007 | 538 | 0.050 |
Why?
| | Chlamydophila Infections | 1 | 2003 | 5 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2006 | 1311 | 0.050 |
Why?
| | Telephone | 1 | 2024 | 176 | 0.050 |
Why?
| | Helicobacter Infections | 1 | 2003 | 30 | 0.050 |
Why?
| | Hepatitis A | 1 | 2003 | 26 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2003 | 84 | 0.050 |
Why?
| | Muscle, Skeletal | 1 | 2013 | 1800 | 0.050 |
Why?
| | Sample Size | 1 | 2022 | 123 | 0.050 |
Why?
| | Time Factors | 3 | 2020 | 7186 | 0.040 |
Why?
| | Child | 8 | 2021 | 22712 | 0.040 |
Why?
| | Mental Status and Dementia Tests | 1 | 2022 | 26 | 0.040 |
Why?
| | Evaluation Studies as Topic | 2 | 2020 | 166 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2024 | 420 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 631 | 0.040 |
Why?
| | Incidence | 2 | 2019 | 2892 | 0.040 |
Why?
| | Dietary Supplements | 2 | 2015 | 576 | 0.040 |
Why?
| | Logistic Models | 2 | 2016 | 2119 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2014 | 2938 | 0.040 |
Why?
| | Kidney Diseases | 1 | 2005 | 427 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2021 | 39 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2003 | 206 | 0.040 |
Why?
| | Pilot Projects | 2 | 2017 | 1894 | 0.040 |
Why?
| | Virion | 1 | 2021 | 111 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2032 | 0.040 |
Why?
| | Kidney | 1 | 2008 | 1499 | 0.040 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 232 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 104 | 0.040 |
Why?
| | Luminescence | 1 | 2020 | 39 | 0.040 |
Why?
| | Serotonin | 2 | 1999 | 294 | 0.040 |
Why?
| | Patient Selection | 2 | 2008 | 726 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2020 | 55 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1054 | 0.040 |
Why?
| | Specimen Handling | 1 | 2021 | 186 | 0.040 |
Why?
| | Opioid Peptides | 1 | 1999 | 9 | 0.040 |
Why?
| | Genetics, Behavioral | 1 | 2019 | 17 | 0.040 |
Why?
| | Escape Reaction | 1 | 1999 | 56 | 0.040 |
Why?
| | Asia, Southeastern | 1 | 1998 | 13 | 0.040 |
Why?
| | Apolipoproteins | 2 | 2004 | 38 | 0.040 |
Why?
| | Computer Simulation | 3 | 2010 | 1026 | 0.040 |
Why?
| | Hyperglycemia | 1 | 2003 | 376 | 0.040 |
Why?
| | Helplessness, Learned | 1 | 1999 | 67 | 0.040 |
Why?
| | Potassium, Dietary | 1 | 2018 | 12 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 433 | 0.030 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 31 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1503 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1997 | 423 | 0.030 |
Why?
| | United Kingdom | 1 | 2019 | 338 | 0.030 |
Why?
| | Methionine | 1 | 2018 | 164 | 0.030 |
Why?
| | Oxidative Stress | 2 | 2016 | 1341 | 0.030 |
Why?
| | Limit of Detection | 1 | 2017 | 97 | 0.030 |
Why?
| | Chromosomes, Human | 1 | 2017 | 41 | 0.030 |
Why?
| | Transcription Factors | 1 | 2005 | 1746 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2017 | 21 | 0.030 |
Why?
| | Absorption | 1 | 1997 | 60 | 0.030 |
Why?
| | Troponin | 1 | 2017 | 49 | 0.030 |
Why?
| | RNA, Viral | 1 | 2021 | 688 | 0.030 |
Why?
| | Anxiety | 2 | 2021 | 1113 | 0.030 |
Why?
| | Hospitalization | 2 | 2021 | 2443 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 1997 | 164 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2017 | 189 | 0.030 |
Why?
| | Models, Biological | 2 | 2010 | 1823 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2017 | 342 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 1046 | 0.030 |
Why?
| | Methemoglobin | 1 | 2015 | 24 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 376 | 0.030 |
Why?
| | Forearm | 1 | 2016 | 140 | 0.030 |
Why?
| | Stress, Physiological | 1 | 1999 | 453 | 0.030 |
Why?
| | Acetylcholine | 1 | 2016 | 206 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2016 | 122 | 0.030 |
Why?
| | Fear | 1 | 1999 | 366 | 0.030 |
Why?
| | Fatty Acids | 1 | 2018 | 452 | 0.030 |
Why?
| | Mice, Congenic | 1 | 2015 | 23 | 0.030 |
Why?
| | Elasticity | 1 | 2015 | 184 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 559 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2008 | 758 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2008 | 2652 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 793 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 529 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 474 | 0.030 |
Why?
| | Pulse Wave Analysis | 1 | 2015 | 266 | 0.030 |
Why?
| | Brain Chemistry | 2 | 2009 | 116 | 0.030 |
Why?
| | Sibling Relations | 1 | 2014 | 10 | 0.030 |
Why?
| | Regression Analysis | 1 | 1997 | 1003 | 0.030 |
Why?
| | Urban Health | 1 | 2014 | 96 | 0.030 |
Why?
| | Rural Health | 1 | 2014 | 87 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1747 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1031 | 0.030 |
Why?
| | Inheritance Patterns | 1 | 2014 | 44 | 0.030 |
Why?
| | Mobility Limitation | 1 | 2014 | 66 | 0.030 |
Why?
| | Unsafe Sex | 1 | 2013 | 61 | 0.020 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 7 | 0.020 |
Why?
| | Age Distribution | 1 | 2014 | 403 | 0.020 |
Why?
| | Condoms | 1 | 2013 | 101 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2202 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1357 | 0.020 |
Why?
| | Vasodilation | 1 | 2015 | 523 | 0.020 |
Why?
| | Research Design | 1 | 1998 | 1137 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 2100 | 0.020 |
Why?
| | Microcirculation | 1 | 2012 | 145 | 0.020 |
Why?
| | Genomics | 1 | 2017 | 842 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1992 | 100 | 0.020 |
Why?
| | Interferons | 1 | 2013 | 188 | 0.020 |
Why?
| | Urinalysis | 1 | 2011 | 80 | 0.020 |
Why?
| | Mice | 3 | 2015 | 18394 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2012 | 367 | 0.020 |
Why?
| | Infusions, Parenteral | 1 | 1991 | 44 | 0.020 |
Why?
| | Muscle Strength | 1 | 2014 | 330 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2015 | 897 | 0.020 |
Why?
| | Phobic Disorders | 1 | 2011 | 35 | 0.020 |
Why?
| | Urban Population | 1 | 2014 | 495 | 0.020 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2011 | 56 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2012 | 610 | 0.020 |
Why?
| | Sodium Chloride | 1 | 1991 | 142 | 0.020 |
Why?
| | Rodentia | 1 | 2010 | 62 | 0.020 |
Why?
| | Neurons | 1 | 1999 | 1642 | 0.020 |
Why?
| | Recovery of Function | 1 | 2014 | 714 | 0.020 |
Why?
| | Animals | 5 | 2015 | 38177 | 0.020 |
Why?
| | Fluid Therapy | 1 | 1991 | 147 | 0.020 |
Why?
| | Nuclear Family | 1 | 2009 | 52 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 397 | 0.020 |
Why?
| | Coronary Disease | 1 | 1992 | 386 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1138 | 0.020 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2009 | 6 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1079 | 0.020 |
Why?
| | Vitamin B 6 | 1 | 2009 | 11 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2010 | 198 | 0.020 |
Why?
| | Dizziness | 1 | 2010 | 101 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2009 | 67 | 0.020 |
Why?
| | Fertility | 1 | 2010 | 168 | 0.020 |
Why?
| | Vitamin B Complex | 1 | 2009 | 40 | 0.020 |
Why?
| | Inflammation | 1 | 2020 | 2881 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 529 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2009 | 127 | 0.020 |
Why?
| | Tetraspanins | 1 | 2008 | 18 | 0.020 |
Why?
| | Medical History Taking | 1 | 2008 | 118 | 0.020 |
Why?
| | Pyrroles | 1 | 2009 | 218 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2008 | 68 | 0.020 |
Why?
| | Sri Lanka | 1 | 2007 | 7 | 0.020 |
Why?
| | Bias | 1 | 2008 | 202 | 0.020 |
Why?
| | Folic Acid | 1 | 2009 | 200 | 0.020 |
Why?
| | Pakistan | 1 | 2007 | 79 | 0.020 |
Why?
| | Anticholesteremic Agents | 1 | 2009 | 154 | 0.020 |
Why?
| | Bangladesh | 1 | 2007 | 62 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2009 | 310 | 0.020 |
Why?
| | Energy Intake | 1 | 2010 | 508 | 0.020 |
Why?
| | Internet | 1 | 2012 | 701 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 382 | 0.020 |
Why?
| | India | 1 | 2007 | 219 | 0.020 |
Why?
| | Creatinine | 1 | 2008 | 510 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 967 | 0.020 |
Why?
| | Genes, Recessive | 1 | 2006 | 78 | 0.010 |
Why?
| | Age of Onset | 1 | 2007 | 551 | 0.010 |
Why?
| | Asthma | 2 | 2010 | 1776 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2007 | 361 | 0.010 |
Why?
| | Data Collection | 1 | 2008 | 635 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1048 | 0.010 |
Why?
| | Linear Models | 1 | 2007 | 854 | 0.010 |
Why?
| | Dyslipidemias | 1 | 2007 | 182 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 1260 | 0.010 |
Why?
| | Placebos | 1 | 2005 | 193 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2005 | 152 | 0.010 |
Why?
| | Vitamin E | 1 | 2005 | 122 | 0.010 |
Why?
| | Heterozygote | 1 | 2005 | 315 | 0.010 |
Why?
| | Body Constitution | 1 | 2004 | 51 | 0.010 |
Why?
| | Smoking Cessation | 1 | 2008 | 439 | 0.010 |
Why?
| | Cross-Cultural Comparison | 1 | 2004 | 84 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1328 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1893 | 0.010 |
Why?
| | Fasting | 1 | 2005 | 277 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 2005 | 263 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 2 | 1999 | 2541 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2005 | 310 | 0.010 |
Why?
| | Hepatitis A virus | 1 | 2003 | 1 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4580 | 0.010 |
Why?
| | Chlamydophila pneumoniae | 1 | 2003 | 12 | 0.010 |
Why?
| | RNA | 1 | 2010 | 940 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 460 | 0.010 |
Why?
| | Asia | 1 | 2003 | 71 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 6007 | 0.010 |
Why?
| | Helicobacter pylori | 1 | 2003 | 45 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2004 | 223 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 2003 | 173 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 17149 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 2003 | 148 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 363 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 610 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2003 | 168 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1049 | 0.010 |
Why?
| | Glucose Intolerance | 1 | 2003 | 142 | 0.010 |
Why?
| | DNA | 1 | 2008 | 1467 | 0.010 |
Why?
| | Parents | 1 | 2010 | 1404 | 0.010 |
Why?
| | Rats | 2 | 1999 | 5616 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2004 | 1327 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2006 | 1169 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1386 | 0.010 |
Why?
| | Reinforcement Schedule | 1 | 1999 | 25 | 0.010 |
Why?
| | Microinjections | 1 | 1999 | 92 | 0.010 |
Why?
| | Electroshock | 1 | 1999 | 145 | 0.010 |
Why?
| | Periaqueductal Gray | 1 | 1999 | 37 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2003 | 673 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2007 | 1243 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1999 | 196 | 0.010 |
Why?
| | Catheterization | 1 | 1999 | 183 | 0.010 |
Why?
| | Morphine | 1 | 1999 | 171 | 0.010 |
Why?
| | Naltrexone | 1 | 1999 | 118 | 0.010 |
Why?
| | Narcotic Antagonists | 1 | 1999 | 206 | 0.010 |
Why?
| | Diet | 1 | 2004 | 1285 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2507 | 0.010 |
Why?
| | Infant | 1 | 2008 | 10101 | 0.010 |
Why?
| | Child, Preschool | 1 | 2008 | 11863 | 0.010 |
Why?
| | Hyaluronoglucosaminidase | 1 | 1991 | 7 | 0.010 |
Why?
| | Tritium | 1 | 1991 | 68 | 0.010 |
Why?
| | Analgesics, Opioid | 1 | 1999 | 1145 | 0.000 |
Why?
| | Depression | 1 | 1999 | 1561 | 0.000 |
Why?
|
|
McQueen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|